rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2010-6-4-46-52rpcardio-898Research ArticleCURRENT QUESTIONS OF CLINICAL PHARMACOLOGYАКТУАЛЬНЫЕ ВОПРОСЫ КЛИНИЧЕСКОЙ ФАРМАКОЛОГИИRECENT ADVANCES IN THE APPLICATION OF HIGH DOSES OF ATORVASTATIN IN PATIENTS WITH CORONARY HEART DISEASEПОСЛЕДНИЕ ДОСТИЖЕНИЯ В ПРИМЕНЕНИИ ВЫСОКИХ ДОЗ АТОРВАСТАТИНА У БОЛЬНЫХ ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦАЕжовМ. В.EzhovM. V.

д.м.н., н.с. отдела проблем атеросклероза Института клинической кардиологии им А.Л. Мясникова 

121552, Москва, 3-я Черепковская ул., 15а

Tretya Cherepkovskaya ul. 15a, Moscow, 121552

marat_ezhov@mail.ruРоссийский кардиологический научно-производственный комплексРоссияRussian Cardiology Research and Production ComplexRussian Federation20101901201664573577Copyright © Ezhov M.V., 20162016Ежов М.В.Ezhov M.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/898

The results of the recently completed clinical studies on the efficacy of atorvastatin in high doses are presented. In these studies high dose atorvastatin therapy was used in patients with acute coronary syndrome, chronic coronary heart disease, and percutaneous coronary interventions. Studies completed in Russia and devoted to efficacy of the high dose atorvastatin therapy are discussed specially.

Представлены результаты исследований последних лет по эффективности высоких доз аторвастатина при остром коронарном синдроме, хронической ишемической болезни сердца чрескожных коронарных вмешательствах. Специально обсуждаются результаты проведенных в России исследований эффективности высоких доз аторвастатина.

аторвастатинвысокие дозыострый коронарный синдромишемическая болезнь сердцачрескожные коронарные вмешательстваatorvastatinhigh dosesacute coronary syndromecoronary heart diseasepercutaneous coronary interventionsReferencesBodenW.E., O'Rourke R.A., TeoK.K. et al. COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356(15):1503-1516.BodenW.E., O'Rourke R.A., TeoK.K. et al. COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356(15):1503-1516.Smith S.C. Jr., Allen J., Blair S.N. et al.; AHA/ACC; National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113(19):2363-72.Smith S.C. Jr., Allen J., Blair S.N. et al.; AHA/ACC; National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113(19):2363-72.Ежов М.В. Польза применения высоких доз аторвастатина в профилактике коронарных осложнений. Consilium medicum 2009; 11(1):125-128.Ежов М.В. Польза применения высоких доз аторвастатина в профилактике коронарных осложнений. Consilium medicum 2009; 11(1):125-128.Schwartz G.G., Olsson A.G., Ezekowitz M.D. et al. Effects of atorvastatin on early recurrentischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285(13): 1711–8.Schwartz G.G., Olsson A.G., Ezekowitz M.D. et al. Effects of atorvastatin on early recurrentischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285(13): 1711–8.Olsson A.G., Schwartz G.G., Szarek M. et al. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur Heart J 2005;26(9):890-6.Olsson A.G., Schwartz G.G., Szarek M. et al. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur Heart J 2005;26(9):890-6.Kinlay S., Schwartz G.G., Olsson A.G. et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003;108(13): 1560-6.Kinlay S., Schwartz G.G., Olsson A.G. et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003;108(13): 1560-6.Kinlay S., Schwartz G.G., Olsson A.G. et al. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation 2004;110(4):386-91.Kinlay S., Schwartz G.G., Olsson A.G. et al. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation 2004;110(4):386-91.Tsimikas S., Witztum J.L., Miller E.R., Schwartz G.G. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation 2004;110(11):1406-12.Tsimikas S., Witztum J.L., Miller E.R., Schwartz G.G. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation 2004;110(11):1406-12.Singh U., Devaraj S., Jialal I., Siegel D. Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome. Am J Cardiol 2008;102(3):321-5.Singh U., Devaraj S., Jialal I., Siegel D. Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome. Am J Cardiol 2008;102(3):321-5.Cannon C.P., Braunwald E., McCabe C.H. et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350(15): 1495–504.Cannon C.P., Braunwald E., McCabe C.H. et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350(15): 1495–504.Murphy S.A., Cannon C.P., Wiviott S.D. et al. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. J Am Coll Cardiol 2009;54(25):2358-62.Murphy S.A., Cannon C.P., Wiviott S.D. et al. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. J Am Coll Cardiol 2009;54(25):2358-62.Pedersen T.R., Cater N.B., Faergeman O. et al. Comparison of Atorvastatin 80 mg/day Versus Simvastatin 20 to 40 mg/day on Frequency of Cardiovascular Events Late (Five Years) After Acute Myocardial Infarction (from the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] Trial). Am J Cardiol 2010; 106(3):354-359.Pedersen T.R., Cater N.B., Faergeman O. et al. Comparison of Atorvastatin 80 mg/day Versus Simvastatin 20 to 40 mg/day on Frequency of Cardiovascular Events Late (Five Years) After Acute Myocardial Infarction (from the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] Trial). Am J Cardiol 2010; 106(3):354-359.Okazaki S., Yokoyama T., Miyauchi K. et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation 2004;110(9):1061-8.Okazaki S., Yokoyama T., Miyauchi K. et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation 2004;110(9):1061-8.Dohi T., Miyauchi K., Okazaki S. et al. Early intensive statin treatment for six months improves long-term clinical outcomes in patients with acute coronary syndrome (Extended-ESTABLISHtrial): a follow-up study. Atherosclerosis 2010;210(2):497-502.Dohi T., Miyauchi K., Okazaki S. et al. Early intensive statin treatment for six months improves long-term clinical outcomes in patients with acute coronary syndrome (Extended-ESTABLISHtrial): a follow-up study. Atherosclerosis 2010;210(2):497-502.Rodés-Cabau J., TardifJ.C., Cossette M. et al.Acute effects of statin therapy on coronary atherosclerosis following an acute coronary syndrome. Am J Cardiol 2009;104(6):750-7.Rodés-Cabau J., TardifJ.C., Cossette M. et al.Acute effects of statin therapy on coronary atherosclerosis following an acute coronary syndrome. Am J Cardiol 2009;104(6):750-7.La Rosa J., Grundy S.M., Waters D.D. et al. for the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352(14): 1425–34.La Rosa J., Grundy S.M., Waters D.D. et al. for the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352(14): 1425–34.Shah S.J., WatersD.D., Barter P. et al. Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery by￾pass surgery. J Am Coll Cardiol 2008;51(20):1938-43.Shah S.J., WatersD.D., Barter P. et al. Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery by￾pass surgery. J Am Coll Cardiol 2008;51(20):1938-43.JohnsonC.,WatersD.D.,DeMiccoD.A. et al.Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeatrevascularization in patientswith previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] Study. Am J Cardiol 2008;102(10):1312-7.JohnsonC.,WatersD.D.,DeMiccoD.A. et al.Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeatrevascularization in patientswith previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] Study. Am J Cardiol 2008;102(10):1312-7.Pedersen T.R., Faergeman O., Kastelein J.J. et al.High dose atorvastatin vs usual dose simvastatin for secondary prevention after myocardial infarction. JAMA 2005; 294 (19): 2437–45.Pedersen T.R., Faergeman O., Kastelein J.J. et al.High dose atorvastatin vs usual dose simvastatin for secondary prevention after myocardial infarction. JAMA 2005; 294 (19): 2437–45.Tikkanen M.J., Szarek M., Fayyad R. et al. Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial. Am Coll Cardiol 2009;54(25):2353-7.Tikkanen M.J., Szarek M., Fayyad R. et al. Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial. Am Coll Cardiol 2009;54(25):2353-7.Di Sciascio G., Patti G., Pasceri V. et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol 2009;54(6):558-65.Di Sciascio G., Patti G., Pasceri V. et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol 2009;54(6):558-65.Briguori C.,Visconti G., FocaccioA. et al. Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol 2009;54(23):2157-63.Briguori C.,Visconti G., FocaccioA. et al. Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol 2009;54(23):2157-63.Kim J.S., Kim J., Choi D. et al. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial. JACC Cardiovasc Interv 2010;3(3):332-9.Kim J.S., Kim J., Choi D. et al. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial. JACC Cardiovasc Interv 2010;3(3):332-9.Gibson C.M., Pride Y.B., Hochberg C.P. et al.; TIMI Study Group. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy. J Am Coll Cardiol 2009;54(24):2290-5.Gibson C.M., Pride Y.B., Hochberg C.P. et al.; TIMI Study Group. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy. J Am Coll Cardiol 2009;54(24):2290-5.Мареев В.Ю., Беленков Ю.Н., Оганов Р.Г. и др. от имени рабочей группы исследования АТЛАНТИКА. Аторвастатин в лечении пациентов ишемической болезнью сердца и дислипидемии высоким общим риском: оценка эффективности и безопасности. Дизайн и основные результаты исследования АТЛАНТИКА. Кардиология 2008; 11: 4–13.Мареев В.Ю., Беленков Ю.Н., Оганов Р.Г. и др. от имени рабочей группы исследования АТЛАНТИКА. Аторвастатин в лечении пациентов ишемической болезнью сердца и дислипидемии высоким общим риском: оценка эффективности и безопасности. Дизайн и основные результаты исследования АТЛАНТИКА. Кардиология 2008; 11: 4–13.Ялымов А.А.,Шехян Г.Г., Быльева А.А., Задионченко В.С. Липидные и нелипидные эффекты аторвастатина у больных с острым коронарным синдромом. Кардиоваскулярная терапия и профилактика 2009; 8(7):64-72.Ялымов А.А.,Шехян Г.Г., Быльева А.А., Задионченко В.С. Липидные и нелипидные эффекты аторвастатина у больных с острым коронарным синдромом. Кардиоваскулярная терапия и профилактика 2009; 8(7):64-72.

The authors declare that there are no conflicts of interest present.